---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000153"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:35:09.917393+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# GRI Bio reports Q3 net loss of $6.3M; cash runway extended into mid Q1 2025

## Summary
- Net loss of $6.3M for nine months ended Sep 30, 2024; R&D expenses $2.9M.
- Cash and cash equivalents $4.7M as of Sep 30, 2024.
- Raised $13.9M gross proceeds since start of 2024, extending runway into mid Q1 2025.
- Interim data from GRI-0621 Phase 2a biomarker study expected Q1 2025; topline Q2 2025.
- Preclinical data presented; Japan patent granted; Australian study authorization received.

## SEC filing metadata
- accession: 0001824293-24-000153
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/0001824293-24-000153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/val-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000153
- JSON: https://secwatch.observer/filing/0001824293-24-000153.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.